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Abstract
The hemolytic uremic syndrome (HUS) is characterized by hemolytic anemia, thrombocytopenia and renal dysfunction. The
typical form of HUS is generally associated with infections by Gram-negative Shiga toxin (Stx)-producing Escherichia coli
(STEC). Endothelial dysfunction induced by Stx is central, but bacterial lipopolysaccharide (LPS) and neutrophils (PMN)
contribute to the pathophysiology. Although renal failure is characteristic of this syndrome, neurological complications
occur in severe cases and is usually associated with death. Impaired blood-brain barrier (BBB) is associated with damage to
cerebral endothelial cells (ECs) that comprise the BBB. Astrocytes (ASTs) are inflammatory cells in the brain and determine
the BBB function. ASTs are in close proximity to ECs, hence the study of the effects of Stx1 and LPS on ASTs, and the
influence of their response on ECs is essential. We have previously demonstrated that Stx1 and LPS induced activation of rat
ASTs and the release of inflammatory factors such as TNF-a, nitric oxide and chemokines. Here, we demonstrate that rat
ASTs-derived factors alter permeability of ECs with brain properties (HUVECd); suggesting that functional properties of BBB
could also be affected. Additionally, these factors activate HUVECd and render them into a proagregant state promoting
PMN and platelets adhesion. Moreover, these effects were dependent on ASTs secreted-TNF-a. Stx1 and LPS-induced ASTs
response could influence brain ECs integrity and BBB function once Stx and factors associated to the STEC infection reach
the brain parenchyma and therefore contribute to the development of the neuropathology observed in HUS.
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Introduction
The epidemic form of hemolytic uremic syndrome (HUS), has
been associated with enterohemorrhagic infections caused by
Shiga toxin (Stx)-producing Escherichia coli (STEC) [1]. HUS is the
most common cause of acute renal failure in children and is
related to endothelial damage of kidney glomeruli and arterioles
and epithelial cell damage induced by Stx, through the interaction
with its globotriaosylceramide (Gb3) receptor [2]. Although Stx is
the main pathogenic factor for HUS development, the inflamma-
tory response is able to potentiate Stx toxicity. In fact, both
bacterial lipopolysaccharide (LPS), and polymorphonuclear neu-
trophils (PMN) play an important role in the full development of
HUS [3].
In severe cases of HUS, endothelial cell (ECs) damage is not
limited to the kidney but extends to other organs, such as the
brain. Central nervous system (CNS) complications are observed
in about 30% of infant population with HUS and brain damage is
the most common cause of death in this disease [4].
Brain ECs are part of the blood brain barrier (BBB), they restrict
the entry of potentially harmful substances and leukocytes from the
bloodstream. In fact, brain ECs damage is thought to be involved
in the disruption of the BBB integrity observed in HUS. However,
the pathogenesis of CNS impairment is not yet fully understood.
Although human brain ECs are relative resistant to Stx effects in
vitro, inflammatory stimuli markedly increase their sensitivity
towards Stx toxicity by increasing Gb3 expression on these cells
[5].
ASTs are inflammatory cells found throughout the CNS and
are surrounding almost entirely the brain endothelium by terminal
processes [6]. The interaction of ASTs with brain ECs determines
the BBB function [7], as soluble factors released by ASTs can
mediate not only the induction but also the maintenance of BBB
properties in brain ECs [8,9]. In response to brain injury, ASTs
become activated and release inflammatory mediators altering the
integrity and permeability of the BBB which can affect neuronal
survival and tissue integrity [10,11]. In addition, ASTs derived
cytokines and chemokines can stimulate the peripheral immune
system and attract peripheral inflammatory leukocytes to the site
of injury [12]. We have recently demonstrated that Stx1 exerts a
direct effect on ASTs although sensitization with LPS potentiates
the effects induced by Stx1. Stx1 induces activation of ASTs and
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secretion of NO, TNF-a and chemokines that promote PMN
attraction [13].
Given the critical anatomical disposition of ASTs and the
influence they exert over ECs from BBB, we hypothesized that the
effects induced by LPS and Stx1 on ASTs may contribute to the
brain ECs damage observed in severe cases of HUS. Thus, the aim
of this study was to evaluate the effects of soluble factors released
by ASTs treated with Stx1 alone, or in combination with LPS on
ECs with brain endothelium properties.
Here we demonstrate that rat ASTs treated with LPS and Stx1
release factors that affect the permeability of brain-like ECs and
increase their susceptibility towards Stx1 cytotoxicity. Additional-
ly, these factors activate ECs, PMN and platelets inducing a
proinflammatory and prothrombic state that promotes PMN and
platelet adhesion to ECs.
Together, our results suggest that ASTs could influence brain
ECs integrity and BBB function once Stx in combination with
bacterial factors reach the brain parenchyma.
Results
Conditioned media from ASTs induce on HUVEC
properties of brain endothelium
In order to accurately model the human BBB, purified ECs
obtained from human umbilical cord veins (HUVEC) were
differentiated into ECs with properties of cerebral endothelium
(HUVECd) by incubating them with conditioned media from
ASTs (CM-ASTs). We assessed the induction of several properties
that characterize brain ECs after 24 h incubation of HUVEC with
CM-ASTs.
Figure 1A shows a significant increase in the activity of alkaline
phosphatase (AlkP) in HUVECd in comparison to HUVEC
maintained in control medium (DMEM). The activity of this
enzyme remained high during 72 hours, even though the CM-
ASTs was removed after 24 hours of incubation (data not shown).
Moreover, as shown in Figure 1B, the permeability to the
passage of horse radish peroxidase (HRP) was decreased in
HUVECd.
Similarly, basal expression of tight junction (TJs) and TJs-
associated proteins, occludin and ZO-1 respectively, were also
increased in HUVECd (Figure 1C and 1D). Additionally,
photomicrographs depicted in Figure 1E corroborated these
results, where an intense expression of ZO-1 and its typical
localization at junctional regions of the cell surface were only
evident in HUVECd.
Finally, as ZO-1 is associated with actin filaments, we
investigated the pattern of distribution of F-actin on HUVECd.
Figure 1E shows structural changes in F-actin on cells cultured
with CM-ASTs. While HUVEC maintained in DMEM showed
an intense pattern of F-actin at the cell periphery (‘‘belt’’ like
distribution), the arrangement of F-actin in HUVECd is mainly
organized in transcytoplasmatic parallel bundles of intense stress
fibers, with a lower degree of peripheral distribution as expected
for brain ECs.
Together, these results support the fact that soluble factors
released by ASTs under basal conditions are able to transdiffer-
entiate non-neural ECs into ECs with brain properties that
simulates the endothelium from BBB.
Stx1 induces on LPS sensitized-ASTs the release of toxic
factors for HUVECd
ASTs response to Stx1 entering the brain parenchyma may
include the secretion of toxic factors for brain ECs located in close
proximity. In order to test this hypothesis, we determined the
toxicity on HUVECd induced by untreated CM-ASTs (CM-
Control) or CM-ASTs treated with LPS and/or Stx1 (CM-LPS,
CM2Stx1 and CM2LPS+Stx1).
After 24 h HUVECd confluent cultures were observed by
optical microscopy to register any change in the cellular
appearance associated with toxicity (shape, refringency or cellular
detachment). Although no apparent changes were observed during
the first 48 h, signs of toxicity were clearly evident at 72 h. Figure 2
shows a slight but significant toxicity induced on HUVECd
incubated with CM2LPS compared with CM-Control.
CM2Stx1 induced even more toxicity on HUVECd. However,
maximal toxicity was observed when HUVECd were incubated
with CM2LPS+Stx1.
These results suggest that Stx1 induces in LPS-sensitized ASTs
the release of toxic factors that contribute to a long-term damage
of endothelial cells with cerebral properties.
Stx1 induces on LPS-sensitized ASTs the release of factors
that increase Gb3 expression and sensitivity of HUVECd
to Stx1
As inflammatory mediators can modulate the expression of the
Stx receptor, the effect of released factors from ASTs treated with
LPS and/or Stx1 on Gb3 expression was evaluated on HUVECd
after a 24 h exposure. Figure 3A shows that the maximum
increase of Gb3 was obtained when HUVECd were treated with
CM2LPS+Stx1. As expected, HUVECd directly treated with
LPS showed an up regulation of the Stx receptor.
To determine whether the enhanced Gb3 expression corre-
lates with an increased toxicity induced by Stx1, HUVECd
treated with the different CM-ASTs were exposed to a sublethal
dose of Stx1. After 18 h, cell death was evaluated by Annexin V
(AV) and propidium iodide (PI) staining (Figure 3B). In
accordance to the results observed for the Gb3 expression, the
percentage of total cell death (AV2PI+ plus AV+PI2 plus
Author Summary
Hemolytic-uremic syndrome (HUS) is generally caused by
Shiga toxin (Stx)-producing Escherichia coli but bacterial
lipopolysaccharide (LPS) and neutrophils (PMN) contribute
to the pathophysiology. Acute renal failure is the main
feature of HUS, but in severe cases, patients develop
neurological complications, which are usually associated
with death. Although the mechanisms of neurological
damage remain uncertain, alterations/injury of brain
endothelial cells (ECs) which constitute the blood-brain
barrier (BBB) is clear. Astrocytes (ASTs) are inflammatory
cells enclosing ECs and are responsible of the normal
function of the barrier. We have recently demonstrated
that Stx1, one of the most common types of Stx, induce an
inflammatory response in LPS-treated ASTs. We then study
the effects of factors released by ASTs in response to LPS
and/or Stx1 on brain-like ECs. We demonstrate that Stx1
induces in LPS-treated ASTs the release of factors that alter
brain properties in ECs, including the permeability; turning
them more susceptible to Stx1 toxic effects. Furthermore,
they activate ECs, neutrophils (PMN) and platelets and
render ECs into a proagregant state promoting PMN and
platelet adhesion. Our results suggest that ASTs could
influence brain ECs integrity and BBB function once Stx in
combination with bacterial factors reach the brain
parenchyma.
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to CM2LPS. Moreover, the cultures treated with
CM2LPS+Stx1 showed the highest susceptibility to Stx1. The
analysis of the quadrants depicted in Figure 3B shows that the
number of cells mapping in the necrotic quadrant (AV2/PI+)i s
relatively small and constant for all treatments, whereas most
cell death is present in the early apoptotic (AV+/PI2)a n dl a t e
apoptotic (AV+/PI+) quadrants, indicating that apoptosis is the
preferential mechanism accounting for HUVECd cell death in
response to CM2LPS+Stx1.
Overall, these results indicate that Stx1 induces on LPS-
sensitized ASTs the release of factors that sensitize HUVECd to
the toxic effects of Stx1, and this correlates with an increased
expression of Gb3 in HUVECd.
Figure 1. Astrocyte conditioned media (CM–ASTs) induce brain endothelium properties on HUVEC. HUVEC were culture with CM-ASTs
(HUVECd) or complete medium DMEM (HUVEC) for 24 h. Thereafter, alkaline phosphatase (AlkP) activity (A) or transendothelial monolayer passage of
horse radish peroxidase (HRP) (B) were spectrophotometrically assessed. Occludin (C) and ZO-1 (D) expression was FACS analyzed and cellular
expression of ZO-1 and distribution of F-Actin were evaluated by microscopy (E) as described in M&M. A: Enzymatic units (EU) of AlkP specific activity
(Mean 6 SEM). * p,0.05 (CM-ASTs vs. DMEM, n=4). B: % Relative permeability (Mean 6 SEM, n=3) of endothelial monolayer to HRP. C and D:
Occludin and ZO-1 relative fluorescence (RF, median fluorescence intensity (MFI)/isotype control MFI) (Mean 6 SEM).*p,0.05 (CM-ASTs vs. DMEM,
n=3). E: Photomicrography showing ZO-1 expression pattern of HUVEC (upper left panel) and HUVECd (upper right panel) of one representative
experiment (n=3). Photomicrography showing maximum intensity Z-projection of F-Actin distribution on HUVEC (lower Left panel) and HUVECd
(lower right panel) of one representative experiment (n=4).
doi:10.1371/journal.ppat.1002632.g001
Figure 2. Increased HUVECd toxicity induced by factors released by LPS and/or Stx1-treated ASTs. HUVECd were stimulated for 72 h
with CM-Control, CM-LPS, CM-Stx1 or CM-LPS+Stx1. Detached dead cells were washed away and the remaining cells were stained and counted by
optical microscopy for toxicity evaluation. % of cytotoxicity respect unstimulated HUVECd (Mean 6 SEM; n=5), *p,0.01 (CM-LPS or CM-Stx1 or CM-
LPS+Stx1 vs. CM-Control); & p,0.01 (CM-LPS or CM-LPS+Stx1 vs. CM-Stx1); ## p,0.01 (CM-LPS+Stx1 vs. CM-LPS). Representative microphotography
of one independent experiment showing HUVECd cultures stained with crystal violet (n=5).
doi:10.1371/journal.ppat.1002632.g002
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that alter the expression of tight junction proteins on
HUVECd and increase toxin transendothelial
translocation
Several lines of evidence suggest that alterations in TJs, or
proteins associated with them, could act as a possible mechanism
leading to an increased BBB permeability [14]. Therefore, we
evaluated the effect of CM-ASTs treated with LPS and/or Stx1 in
the expression of proteins required for tight junction maintenance
and BBB permeability. Figure 4A and 4B depicts that both
CM2LPS and CM2Stx1 induced a significant decrease in the
expression of ZO-1 and occludin on HUVECd compared to cells
exposed to CM-Control. Nevertheless, this reduction was even
more evident when HUVECd were stimulated with
CM2LPS+Stx1. In agreement with these results, micrographs
depicted in Figure 4C show the reduced ZO-1 expression. In this
sense, the intense staining of ZO-1 observed in the periphery of
adjacent HUVECd treated with CM-Control was significantly
reduced in those cells exposed to CM-LPS or CM2Stx1, where
only a few areas of low ZO-1 expression were evidenced.
Furthermore, ZO-1 was absent in HUVECd stimulated with
CM2LPS+Stx1, even at the contact areas between adjacent cells.
In addition, micrographies shown in Figure 4C illustrate that F-
actin in HUVECd exposed to CM-Control were more promi-
nently arranged defining transcytoplasmatic stress fibers. On the
contrary, in HUVECd stimulated with CM2LPS and/or Stx1, a
peripheral localization of F-actin was observed. In addition, a
cellular retraction was observed, with more pronounced intercel-
lular spaces.
Factors released by ASTs may increase HUVECd permeability
allowing the passage of Stx1 across the endothelium. To test this
hypothesis we determined the translocation of Stx1 across
HUVECd treated with the different conditioned media. HUVECd
in transwell upper chambers were stimulated for 24 h with
CM2LPS and/or Stx1. Then CM-ASTs were removed, cells
were washed, and Stx1 was added. After 30 min. the medium in
the lower chamber was recovered and the presence of Stx1 was
determined by the Vero toxicity bioassay, a cell line highly
sensitive to the toxin. Figure 4D shows a significant increase in the
percentage of Vero cytotoxicity mediated by Stx1-translocated
through HUVECd monolayer pretreated with CM2LPS or
CM2Stx1. This increase was even higher for HUVECd incubated
with CM2LPS+Stx1.
These results indicate that factors released by ASTs sensitized
with LPS and treated with Stx1 altered the expression of TJs
proteins and TJs-associated proteins on HUVECd, and induced
an increase of HUVECd permeability, allowing the translocation
of Stx1 across the endothelium.
Figure 3. Factors released by Stx1 and/or LPS-treated ASTs increase Gb3 expression and Stx1 susceptibility in HUVECd. HUVECd
were stimulated with CM-Control, CM2LPS, CM2Stx1, CM2LPS+Stx1 or with 0.5 mg/ml de LPS (HUVECd+LPS) for 24 h. Then stimulus was removed
and Stx1 was added for another 18 h. Finally, Gb3 expression (A) and toxin induced cell death (B) were evaluated by flow cytometry (FACS). A:
Relative Fluorescence (RF) of Gb3 (Mean fluorescence intensity relative to unstimulated HUVECd, Mean 6 SEM). *p,0.05 (CM-Control vs. CM2LPS);
**p,0.0002 (CM-Control vs. CM2LPS+Stx1 or HUVECd+LPS, n=3). Left panel is a representative histogram plot of one independent experiment. B:%
of total Stx1 induced cell death (Mean 6 SEM) determined by PI/Annexin V binding assay. Total dead cells were defined as the sum of necrotic (PI+/
AV2), late apoptotic (PI+/AV+) and early apoptotic (PI2/AV+) HUVECd cells. *p,0.05 (CM-Control vs. CM2LPS or CM2LPS+Stx1);
#p,0.05,
##p,0.001 (CM2LPS+Stx1 vs. CM2LPS and CM2LPS+Stx1 respectively, n=4). The left panel represents a dot-plot of one independent experiment.
doi:10.1371/journal.ppat.1002632.g003
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induce activation of HUVECd
In order to determine whether factors released by ASTs treated
with LPS and/or Stx1 induce activation of HUVECd, we
evaluated the expression of adhesion molecules such as ICAM-1
and E-selectin, and the release of procoagulant molecules, such as
the von Willebrand Factor (vWF).
Figures 5A and B show that the expression of ICAM-1 and E-
selectin was significantly increased exclusively on HUVECd
stimulated with CM2LPS+Stx1. The expression of these
molecules was similar to that obtained for HUVECd stimulated
directly with LPS. Figure 5C shows an increase in vWF
secretion induced by CM2LPS. Nevertheless, the highest
secretion was observed when HUVECd were stimulated with
CM2LPS+Stx1.
These results suggest that Stx1 causes the release of factors on
LPS-sensitized ASTs that induce the activation and a prothrom-
botic state on HUVECd.
ASTs treated with LPS and Stx1 release factors that
induce activation of PMN and increase PMN
transendothelial migration
Numerous studies have suggested that activation of leukocytes is
critical for endothelial damage. Therefore, we analyzed whether
factors released by ASTs treated with LPS and/or Stx1 induce
PMN activation. Purified PMN were incubated with the different
CM-ASTs and the expression of PMN-activation markers was
evaluated. An increase in the expression of CD11b (Figure 6A) and
CD66b (Figure 6B) was found on PMN stimulated with
CM2LPS+Stx1 compared with CM-Control.
Figure 4. Factors released by LPS and/or Stx1-treated ASTs increase transendothelial permeability by reducing tight-junctions
proteins expression on HUVECd. HUVECd seeded on culture plates (A,B,C) or in upper transwell chamber (D) were stimulated during 24 h with
CM-Control, CM2LPS, CM2Stx1 or CM2LPS+Stx1. ZO-1 (A) and occludin (B) expression were evaluated by FACS. ZO-1 expression and F-Actin cellular
distribution were evaluated by confocal microscopy (C). Stx1 passage across HUVECd monolayer was determined using the Vero cell cytotoxicity
bioassay after 30 min of toxin translocation to the lower transwell chamber (D). (A) ZO-1 or (B) occludin relative median fluorescence intensity (RF)
(Mean 6 SEM, n=4). *p,0.05 (CM2LPS or Stx1 vs. CM-Control); **p,0.001 (CM2LPS or CM2LPS+Stx1 vs. CM-Control); ***p,0.0001 (CM2LPS+Stx1
vs. CM-Control);
##p,0.001(CM2LPS+Stx1 vs. CM2LPS or CM2Stx1). Lower panel: a representative histogram of an independent experiment is
shown. C: Microphotographs showing ZO-1 expression pattern on CM-treated HUVECd (upper panels) of an independent experiment (n=3).
Microphotographs showing maximum intensity Z-projection of F-Actin distribution on CM-treated HUVECd (lower panels) of an independent
experiment (n=4). D: Stx1 translocation measured as % Vero of cytotoxicity respect to Vero cell cultured in DMEM (Mean 6 SEM; n=3). *p,0.05 (CM-
LPS or CM-Stx1 vs. CM-Control; **p,0.001 (CM2LPS+Stx1 vs. CM-Control);
#p,0.05 (CM2LPS+Stx1 vs. CM2LPS).
doi:10.1371/journal.ppat.1002632.g004
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PLoS Pathogens | www.plospathogens.org 5 March 2012 | Volume 8 | Issue 3 | e1002632Figure 5. Factors released by LPS and Stx1-treated ASTs increased HUVECd activation. HUVECd were stimulated with CM-Control,
CM2LPS, CM2Stx1, CM2LPS+Stx1 or with 0.5 mg/ml de LPS (HUVECd+LPS). ICAM-1 (A) and E-selectin (B) expression was evaluated by FACS after
12 h or 3 h of stimulation, respectively. The release of von Willebrand Factor (vWF) was quantified by ELISA (C). A: ICAM-1 relative median
fluorescence (RF) (Mean 6 SEM, n=4). *p,0.05 (LPS+Stx1 vs. Control); **p,0.001 (HUVEC+LPS vs. CM-Control, n=3). B: E-selectin relative median
fluorescence (RF) (Mean 6 SEM, n=4). **p,0.005 (CM2LPS+Stx1 vs. Control); *p,0.05 (CM2HUVEC+LPS vs. CM-Control, n=4). Representative
histograms of one independent experiment were plotted in the lower panels. C: Concentration (ng/ml) of vWF released (Mean 6 SEM, n=6).
**p,0.01 (CM2LPS vs. CM-Control); **p,0.001 (CM2LPS+Stx1 vs. CM-Control);
#p,0.05 (CM2LPS+Stx1 vs. CM2LPS).
doi:10.1371/journal.ppat.1002632.g005
Figure 6. Factors released by LPS and Stx1-treated ASTs induce activation and migration of PMN through HUVECd. PMN were
stimulated with CM-Control, CM2LPS, CM2Stx1 or CM2LPS+Stx1. CD11b (A) or CD66b (B) expressions were evaluated by FACS at 40 or 90 min after
stimulation, respectively. In (C), HUVECd seeded on the upper chamber of a transwell were stimulated with CM-Control, CM2LPS, CM2Stx1 or
CM2LPS+Stx1 for 24 h. PMN migration across the HUVECd monolayer was determined microscopically after 1.5 h of co-culture. Disruption of
HUVECd monolayer integrity was evaluated after PMN transmigration by staining HUVECd with May Gru ¨nwald-Giemsa (D). A: CD11b relative median
fluorescence (RF) (Mean 6 SEM, n=4). **p,0.005 (CM2LPS+Stx1 vs. CM-Control);
#p,0.05 (CM2LPS+Stx1 vs. CM2Stx1). Representative histogram
of one independent experiment is plotted in the right panel. B: CD66b relative median fluorescence (RF) (Mean 6 SEM, n=4). **p,0.001 (LPS+Stx1
vs. Control);
##p,0.005 (CM2LPS+Stx1 vs. CM2Stx1). A Representative histogram of one independent experiment is plotted in the right panel. C:
Transmigration of PMN (PMN/ml) (Mean 6 SEM, n=3). *p,0.05 (CM2LPS vs. CM-Control); **p,0.01 (CM2Stx1 or CM2LPS+Stx1 vs. CM-Control);
##p,0.01 (CM2LPS+Stx1 vs. CM2Stx1);
###p,0.001 (CM2LPS+Stx1 vs. CM2LPS, n=3). D: Representative microphotographs depicting HUVECd
monolayer disruption after PMN transmigration (n=3).
doi:10.1371/journal.ppat.1002632.g006
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ASTs can account for both recruitment and activation of
leukocytes [15,16]. Therefore, we assessed whether factors
released from ASTs treated with LPS and/or Stx1 were able to
promote PMN migration across HUVECd. For this purpose,
HUVECd placed in transwell upper chambers were stimulated for
24 h with CM2LPS and/or Stx1. Afterward, PMN were added in
the upper chamber and the number of migrated PMN in the lower
chamber was determined after 1.5 h. Results depicted in Figure 6C
reveal that the concentration of PMN that migrated through the
endothelial monolayer increased significantly with the CM2LPS
or CM2Stx1 compared with CM-Control. However,
CM2LPS+Stx1 induced the maximal PMN transmigration.
As the passage of leukocytes through ECs may contribute to the
disruption of the cellular monolayer, HUVECd were vigorously
washed in order to eliminate non-migrated PMN and then
monolayers were stained. Micrographies depicted in Figure 6D
show that the monolayer architecture of HUVECd was disrupted
by transmigration of PMN on those cultures treated with
CM2LPS or CM2Stx1. However, disruption of HUVECd
architecture as a result of PMN transmigration was higher when
HUVECd were stimulated with CM2LPS+Stx1. These effects
were not observed in HUVECd stimulated with the different CM-
ASTs in the absence of PMN, dismissing the possibility that the
CM-ASTs alone could cause these effects (data not shown).
In summary, these results suggest that Stx1 induces on LPS-
sensitized ASTs the release of factors that activate PMN and
promote their transmigration through endothelium, causing in
turn, the disruption of the endothelial monolayer.
Stx1 induces on ASTs sensitized with LPS the release of
factors that increase the adhesion of PMN and sensitivity
to PMN-mediated damage in HUVECd
PMN-mediated endothelial damage can seriously compromise
vasculature and associated tissue functions. The adhesion of PMN
to endothelium and the consequent cytotoxicity is magnified by
the expression of endothelial ICAM-1 and E-selectin. Therefore,
we tested whether ASTs exposed to the toxin could promote PMN
adhesion to HUVECd and damage. HUVECd were stimulated
with CM2LPS and/or Stx1. After removal of the stimulus,
purified PMN were added and non-adhered PMN were removed
3 h later by vigorous washing. The percentage of PMN-derived
alkaline phosphatase activity (AlkP) in the remaining attached cells
was measured in order to evaluate PMN adhesion to HUVECd.
On the other hand, to assess PMN-mediated cytotoxicity, the co-
cultures were washed out after 8 h and stained with crystal violet.
The percentage of cytotoxicity was determined microscopically by
counting the remaining attached HUVECd. HUVECd were easily
distinguishable from PMN because of their differences in shape
and staining intensity.
Figure 7A shows an increase in the percentage of PMN-derived
AlkP activity when HUVECd were stimulated with
CM2LPS+Stx1. In addition, Figure 7B shows that the CM-LPS
or CM2Stx1 sensitize HUVECd to PMN-mediated toxicity in
comparison to HUVECd stimulated with CM-Control. However,
this effect was further induced when HUVECd were stimulated
with CM2LPS+Stx1. In order to determine whether PMN-
mediated cytotoxicity is dependent on the direct interaction with
HUVECd, we performed the same experiment but seeding PMN
in the upper chamber of a transwell. Figure 7C shows that under
this condition PMN-mediated cytotoxicity was avoided.
To sum up, these results indicate that Stx1 induces on LPS-
sensitized ASTs the release of factors that promote PMN adhesion
to HUVECd and increase their susceptibility to PMN-mediated
damage, which depends on PMN contact with HUVECd.
Stx1 induces on LPS-sensitized ASTs the release of factors
that activate platelets and promote their adhesion to
HUVECd
Under physiological conditions the endothelium produces many
substances that prevent platelets activation and blood clots of
fibrin [17]. In this sense, ASTs surrounding compromised
endothelium could contribute to platelet activation/adhesion
and subsequent brain microthrombi generation. In order to test
this hypothesis, we determined whether factors released by ASTs
treated with LPS and/or Stx1 induce platelets activation and
adhesion to endothelium. As shown in Figure 8A expression of P-
selectin and the percentage of activated platelets were increased by
the CM2LPS+Stx1. To assess the platelets adhesion to endothe-
lium, HUVECd were stimulated with CM2LPS and/or Stx1 for
24 h, and platelets were seeded on HUVECd. After 1.5 h, free
platelets were removed by repeated washings, and the remaining
adherent platelets were assessed by measuring acid phosphatase
activity (AcP). The figure 8C shows an increase in the percentage
of AcP activity induced by CM2LPS+Stx1.
Results indicate that in response to Stx1, LPS-sensitized ASTs
released factors that activate platelets and promote their adhesion
to HUVECd.
The inhibition of NF-kB or the blockage of secreted TNF-
a in ASTs exposed to LPS and Stx1 abrogated the
response of HUVECd and platelets and PMN
We have previously determined that inhibiting NF-kB with
BAY 11-7082 or blocking secreted TNF-a activity with Etanercept
prevented the activation and the inflammatory response on LPS-
sensitized ASTs exposed to Stx1 [13]. Therefore, we investigated
whether the effects observed in HUVECd, PMN and platelets
were dependent on NF-kB activation, and particularly on the
production of TNF-a by ASTs stimulated with LPS and Stx1.
Thus, the experiments were conducted with CM-ASTs of ASTs
that were pretreated with Etanercept or BAY 11-7082 before the
addition of LPS and Stx1. As shown in Figure 9, under these
conditions neither the increment in Gb3 expression (Figure 9A)
nor the increased sensitivity to the toxin (Figure 9B) was observed
in HUVECd. Likewise, the declined expression of ZO-1 or
occludin were not detected (Figure 9C). A similar behavior was
found when endothelial activation was analyzed through ICAM-1
and E-selectin expression (Figure 9D) and the release of vWF
(Figure 9E). Furthermore, neither PMN (Figure 9F) nor platelet
(Figure 9G) activation was observed.
Overall, the results indicate that NF-kB activation on
LPS+Stx1-treated ASTs is necessary for the secretion of factors
that induce activation of HUVECd, PMN and platelets, as well as
for the increased expression of the Stx1 receptor and sensitivity to
the toxin in HUVECd. Moreover, TNF-a seems to mediate these
effects.
Discussion
CNS complications are recognized as a major determinant of
morbidity and mortality in the acute phase of STEC infections.
Although, the pathogenesis of CNS involvement is not yet fully
understood, the disruption and/or increased permeability of the
BBB are central events in the CNS complications observed during
the acute phase of HUS [18]. Stx is a macromolecule, and
although in normal condition it should not be able to enter to
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that the toxin crosses the barrier. Moreover, the toxin have been
found associated not only to brain ECs but also on parenchymal
cells close to perivascular spaces including neurons and ASTs
[19,20,21] suggesting that during STEC infection the BBB is
altered. In addition, several in vivo studies found Stx in spinal cord
fluid during the initials hours after toxin systemic inoculation,
whereas pathological changes of blood vessels are noted at later
stages [22]. In line with this, neuronal abnormalities appear before
any vascular affection, suggesting the importance of events
Figure 8. LPS and Stx1-treated ASTs release factors that increase platelet activation and adhesion to HUVECd. Platelets or HUVECd
were stimulated with CM-Control, CM2LPS, CM2Stx1 or CM2LPS+Stx1. After 1.5 h density expression of P-selectin and the % of activated platelets
was determined by FACS (A and B). To determine platelets adhesion to CM-stimulated HUVECd (C), platelets were seeded on stimulated HUVECd
(CM-Control/Pt, CM2LPS/Pt, CM2Stx1/Pt, CM2LPS+Stx1/Pt). Free platelets were washed away after 1.5 h and the platelet acid phosphatase (AcP)
percentage of enzymatic activity (% EA) was determined by spectrophotometry. As control of maximal platelet adhesion, total platelets on untreated
HUVECd were left unwashed (Total Pt). A: P-selectin relative median fluorescence (RF) (Mean 6 SEM, n=6). *p,0.05 (CM2LPS+Stx1 vs. CM-Control);
#p,0.05 (CM2LPS+Stx1 vs. CM2Stx1 or CM2LPS) (Upper graph). % of activated platelets was defined by high P-selectin expressing subpopulation.
*p,0.05 (CM2LPS+Stx1 vs. CM-Control) (Lower graph). B: Representative FACS analysis of an independent experiment showing histogram and
scatter plots. C: AcP (% EA) respect to % EA of Total Pt (Mean 6 SEM, n=6). *p,0.05 (CM2LPS+Stx1/Pt vs. CM-Control/Pt);
#p,0.05 (CM2LPS+Stx1/
Pt vs. CM2LPS/Pt, n=6).
doi:10.1371/journal.ppat.1002632.g008
Figure 7. Factors released by LPS and/or Stx1-treated ASTs induce increased PMN adhesion and HUVECd toxicity. HUVECd were
stimulated with CM-Control, CM2LPS, CM2Stx1 or CM2LPS+Stx1 for 24 h. Then, PMN were seeded onto pretreated HUVECd (CM-Control/PMN,
CM2LPS/PMN; CM2Stx1/PMN or CM2LPS+Stx1/PMN). (A) After 3 h of co-culture, non-adhered PMN were washed away and the percentage of
enzymatic activity (% EA) of alkaline phosphatase (AlkP) from adhered PMN was determined by spectrophotometry. As a control of maximal PMN
adhesion, total PMN on untreated HUVECd were left unwashed (Total PMN). (B) To determine PMN mediated endothelial toxicity, PMN and dead
HUVECd were washed after 8 h of co-culture and cultures were stained with crystal violet and the % of cytotoxicity was determined microscopically
by counting the remaining attached HUVECd. In (C), contact dependency of PMN-mediated cytotoxicity was evaluated as (B), seeding PMN on the
upper chamber of a transwell (‘‘PMN’’ written in superscript) to avoid contact with CM-ASTs-stimulated HUVECd seeded in the lower chamber
(CM2Stx1/
PMN or CM2LPS+Stx1/
PMN). A: % of AlkP activity (% EA) respect to total PMN (Mean 6 SEM, n=6). **p,0.001 (CM2LPS+Stx1/PMN vs. CM-
Control/PMN); #p,0.05 (CM2LPS+Stx1/PMN vs. CM2LPS o CM2Stx1/PMN). B: % of Cytotoxicity respect to HUVECd without PMN (Mean 6 SEM,
n=3). *p,0.05 (LPS o Stx1 vs. Control); **p,0.001 (CM2LPS+Stx1/PMN vs. CM-Control/PMN); #p,0.01 (CM2LPS+Stx1/PMN vs. CM2Stx1/PMN);
##p,0.01 (CM2LPS+Stx1/PMN vs. CM2LPS/PMN). C: % of Cytotoxicity respect to HUVECd without PMN (Mean 6 SEM, n=2). **p,0.0001
(CM2LPS+Stx1/PMN vs. CM2LPS+Stx1/
PMN); #p,0.01 (CM2Stx1/PMN vs. CM2Stx1/
PMN).
doi:10.1371/journal.ppat.1002632.g007
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pathology observed in HUS.
Even though neurological commitment is epidemiologically
related to Stx2 variant [23], growing experimental evidence
demonstrated the neurotoxicity of Stx1 [13,24,25,26,27,28,29].
Moreover, Stx1 have been shown to be in some models, even more
neurotoxic than Stx2 [30].
Astrocytes (ASTs) are the most abundant inflammatory cells
[31,32], they are surrounding the cerebral endothelium and their
interaction with ECs determines the BBB phenotype and function
[8,9,33,34]. ASTs are therefore in a critical position to influence
brain ECs integrity and the BBB function, once Stx and factors
associated to the STEC infection reach the brain parenchyma.
Although the astrocytic inflammatory response elicited by Stx in
vivo or in HUS patients has not been studied until the moment,
there are two reports in the literature using animal models that
demonstrated ASTs activation and alteration after Stx inoculation
[33,34]. In addition, local production of TNF-a has been
described in mouse brains after STEC infection [35]. We have
recently demonstrate that Stx1 exerts a direct action on rat ASTs,
although sensitization with LPS potentiates Stx1-induced effects,
by means of increasing Gb3 expression, revealing activation of
ASTs and the development of an inflammatory response
characterized by the secretion of nitric oxide (NO), TNF-a and
chemokines that promote PMN attraction. Moreover, ASTs
derived TNF-a is a pivotal effector molecule that amplifies the
Stx1 effects on LPS-sensitized ASTs [13]. Therefore, it is highly
probable that mediators released by activated AST in response to
Stx (and LPS) are influencing ECs functionality in vivo.
In the present work we seek to obtain new knowledge for the
role of ASTs on brain endothelial dysfunction in an attempt to
further address the contribution of the local elicited inflammatory
response to the neurophatology of HUS.
Our model uses conditioned-media (CM) from rat ASTs (that
express the Stx receptor Gb3), whereas ASTs from human biopsies
were found negative for Gb3 expression [36]. However, activated
human ASTs/astrocytoma cells do express Gb3 [37]. On the other
hand, the LPS receptor (TLR4) has been shown to be expressed in
human ASTs [38,39,40]. Therefore, although experiments using
human primary ASTs are necessary to confirm our current results,
we can speculate that during the disease process activation of
ASTs by LPS, systemic inflammatory mediators, or other bacterial
products, may lead to the induction of Gb3 in ASTs, triggering a
local inflammatory response that will be, in turn, amplified by Stx.
In this context, the results originated from the treatments with
CM2LPS and CM2LPS+Stx1 may most likely represent the
HUS scenario.
Peripheral endothelial cells can be induced to differentiate into
brain capillary ECs by soluble factors released by ASTs
[7,36,37,38,39]. Here, we differentiated HUVEC into ECs that
adopt characteristics that coincide with those present in human
brain ECs (HUVECd), which allowed us modeling more
accurately human BBB. In this regard, we observed an increase
in AlkP activity, an increased expression of ZO-1 and occludin and
a reorganization of F-actin. These observations are consistent with
those reported by others [38,39]. In addition, we observed a
decreased permeability to horse radish peroxidase (HRP) in
HUVECd when compare to non-differentiated HUVEC, similar
to the decrease in permeability observed in a comparative study
using brain microvascular ECs and HUVEC [40]. Although we
are aware of the limitations of our model, since HUVECd are not
exactly ECs from brain origin, the use of human primary brain
cells is restricted by the unavailability of experimental material,
which is usually obtained from surgical material and often cannot
be considered as ‘‘healthy’’ tissue [41,42]. Additionally, some
characteristics of the in vivo BBB are lost in culture and this is
compensated by co-culturing with ASTs or their CM [8,43]. On
the other hand, the use of immortalized brain endothelial cell lines
does not assure an exactly similar behavior in culture as in the
brain. An advantage of using HUVECd primary cultures obtained
from HUVECs of different donors is that the heterogeneity of
responses that exist among different individuals is maintained, and
the variability obtained in the results better represents the
variability found in HUS patients, in contrast of using a cell line
with the same genetic background. Taken all this considerations
into account, we consider that brain properties elicited in
HUVECd, by incubation of HUVEC with CM of ASTs, are
enough representative of brain ECs.
Then, in order to evaluate if the astrocytic response to LPS
and/or Stx1 could altered properties of ECs forming the BBB, we
studied the effects of soluble factors released by ASTs exposed to
LPS and/or Stx1 on HUVECd. We found that TNF-a released
from LPS-sensitized ASTs treated with Stx1 was able to increase
Gb3 expression on HUVECd and this correlated with a higher
susceptibility towards Stx1 toxic effects. These findings are in
agreement with other reports using human brain ECs [27,44].
On the other hand, LPS-sensitized ASTs stimulated with Stx1
released factors that, only in the long term, turn out to be toxic for
HUVECd. Although astrocytic factors responsible for HUVECd’s
toxicity were not determined in this work, TNF-a has been
proposed as the molecule responsible for ASTs mediated
cytotoxicity on oligodendrocyte [45] and neurons [46]. However,
in vitro, TNF-a is not toxic for brain ECs cultures by its own, but it
resulted in a surprising synergism when combined with reactive
species [47]. In this respect, NO liberated in response to LPS and
Stx1 may act in combination with TNF-a inducing long term
HUVECd death. Another plausible explanation is that the protein
synthesis inhibiting activity of Stx1 prevents the expression of a
host response factor by ASTs that is necessary for maintenance of
EC viability [48,49,50]. In this sense, down-regulation of cell
survival factors, in addition to the release of cytotoxic factors, may
also contribute to long term ECs death.
The commitment of the TJs is a distinctive characteristic in
neuroinflamatories diseases [51]. Numerous inflammatory sub-
Figure 9. NF-kB inhibition or TNF-a blockade in LPS and Stx1-treated ASTs inhibit the effects of CM-ASTs. HUVECd, PMN or platelets
were stimulated with CM-Control, or CM2LPS+Stx1 or CM of ASTs treated with BAY11-7082 o Etanercept before the addition of LPS and Stx1 (CM2
LPS+Stx1/BAY 11-7082; CM-Etanercept/LPS+Stx1). A: HUVECd Gb3 relative median fluorescence (RF) (Mean 6 SEM). *p,0.05 (CM2LPS+Stx1 vs. CM-
Etanercept/LPS+Stx1); **p,0.01 (CM2LPS+Stx1 vs. CM-BAY 11-7082/LPS+Stx, n=3). Histogram of an independent experiment is plotted in the right
panel. B: HUVECd % Cytotoxicity (Mean 6 SEM, n=3) is determined by PI/Annexin V binding assay. *p,0.05 (CM2LPS+Stx1 vs. CM-Etanercept/
LPS+Stx1); **p,0.01 (CM2LPS+Stx1 vs CM-BAY11-7082/LPS+Stx1). C: HUVECd ZO-1 or occludin relative median fluorescence (RF) (Mean 6 SEM,
n=4). *p,0.05 (CM2LPS+Stx1 vs. CM-Etanercept or BAY11-7082/LPS+Stx1). D: HUVECd ICAM-1 or E-selectin relative median fluorescence (RF) (Mean
6 SEM, n=4). *p,0.05 (CM2LPS+Stx1 vs. CM-Etanercept or BAY11-7082/LPS+Stx1, n=3). E: vWF release (ng/ml) (Mean 6 SEM, n=4). *p,0.05
(CM2LPS+Stx1 vs. CM-Etanercept or BAY11-7082/LPS+Stx1. F: PMN RF of CD11b or CD66b (Mean 6 SEM, n=4). *p,0.05 (CM2LPS+Stx1 vs. CM-
Etanercept o BAY11-7082/LPS+Stx1); **p,0.01 (CM2LPS+Stx1 vs. CM-Etanercept/LPS+Stx1). G: Platelet RF of P-selectin and % of activated platelets
(Mean 6 SEM, n=6). *p,0.05 (CM2LPS+Stx1 vs. CM-Etanercept or BAY11-7082/LPS+Stx1).
doi:10.1371/journal.ppat.1002632.g009
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NO and LPS [52,53]. In vivo studies have demonstrated that an
increment in the barrier permeability is associated with low levels
of expression of ZO-1, occludin and actin filaments [54]. Here we
determined that factors released by ASTs in response to LPS or
Stx1, and especially by the combination of LPS and Stx1, induced
an important decrease in occludin and ZO-1 expression in
HUVECd. Moreover, this correlated with a significant peripheral
localization of the ZO-1 protein, which has been shown to impact
on the function of the BBB. Even though there are no concrete
evidences that determine how this redistribution happens, it is
believed to be associated with the reorganization of actin filaments,
which are connected to the proteins of the TJs complex through
ZO-1 [55,56]. The results shown in this work indicate, for the first
time, that ASTs inflammatory response induced by LPS and Stx
and particularly ASTs-derived TNF-a, alters these molecules
contributing to the increased endothelial permeability observed in
HUS. Although in vivo studies must be performed to corroborate
this hypothesis, studies on other cerebral pathologies support this
possibility [53,57]. In this sense, A ´lvarez et al. demonstrated in a
murine model of cerebral inflammation that activated ASTs
expressing BBB regulatory cytokines were juxtaposed to blood
vessels exhibiting increased permeability [58].
An additional factor that can contribute to the loss of integrity of
the BBB is the migration of PMN induced by chemotactic stimuli
[59]. Migration across the BBB of PMN may initiate pathogenic
events, leading to microvascular plugging, stasis, and thrombosis
[60,61]. PMN may migrate across the endothelial monolayer at
cell-cell junctions by a paracellular route and/or by a transcellular
pathway that involves migration of PMN at non-junctional
locations. Here, we found an augmented migration of PMN
across HUVECd treated with CM2LPS+Stx1. Given the
increased permeability observed in HUVECd treated with
CM2LPS+Stx1, and in concordance with a markedly reduction
of tight junction proteins (ZO-1 and occludin), we can speculate
that PMN more likely take a paracellular route to transmigrate,
since this route is highly dependent on barrier function
deregulation. Moreover, it has been recently demonstrated that
PMN preferentially migrate across the BBB via the transcellular
route when the barrier function is intact [62] Although PMN
transmigration is not usually associated with disruption of the
endothelial linearity, the presence of additional factors that induce
PMN degranulation, such as TNF-a, can cause destruction of the
vascular endothelial architecture due to the release of proteolytic
enzymes [63,64]. The results obtained here indicate that, in
addition to the increased endothelial permeability, PMN transmi-
gration induced by factors secreted by ASTs in response to LPS
and Stx1 was associated to the destruction of the endothelial
monolayer linearity, compromising even more the integrity of the
BBB. Additionally, factors released by treated ASTs induced
PMN-mediated endothelial toxicity, and in agreement with other
reports [65,66], this was dependent on the close interaction/
contact between HUVECd and PMN.
All together, these results indicate that the systemic and local
(from perivascular ASTs) inflammatory responses increase the
BBB permeability, and at the same time, potentiate the damage of
ECs triggered by Stx and factors associated to the infection.
Endothelial dysfunction is crucial for the development of
microangiopathic injuries in HUS [67,68], and a vast bibliography
suggests that the interaction between activated leukocytes
(especially PMN), platelets and ECs amplifies and extends renal
damage [66,69,70]. However, so far no work regarding HUS-
associated neuropathology contemplates the contribution of the
intracerebral inflammation and its effect on ECs that comprise the
BBB. Among the critical events commonly involved in CNS
affection in HUS, edema, microthrombi and ischemic changes are
found [71,72]. Autopsy material from patients with HUS reveals
thrombosis of capillaries in kidney, lung, liver and brain. Both
damage and stimulation with inflammatory mediators suppress the
anticoagulant properties of endothelium, promoting a procoagu-
lant condition. We determined that factors secreted by ASTs
treated with LPS and Stx1 directly induced HUVECd, PMN and
platelet activation, and increased both PMN and platelet adhesion
to activated HUVECd. Therefore, these events may contribute to
the cerebral inflammation in HUS triggering the formation of
thrombi and altering ECs integrity. Moreover, activation of
HUVECd, PMN and platelets was not observed when ASTs were
pretreated with BAY 11-7082 and exposed to LPS and Stx1,
suggesting that inflammatory factors secreted by means of NF-kB
activation were responsible for the effects observed in these cells.
Furthermore, the blockade of ASTs released TNF-a by Etanercept
also prevented these effects.
The results presented herein suggest that NF-kB and TNF-a
could be target molecules to prevent or diminish the CNS
complication observed in HUS patients. Several in vivo studies of
different CNS pathologies demonstrated that suppression of ASTs
activation and their inflammatory response resulted in reduced
disease severity and improved functional recovery [73]. In addition,
recent reports showed clinical improvement in patients with
Alzheimer and related disorders following the perispinal adminis-
tration of Etanercept, suggesting that Etanercept has the ability to
penetrate into the cerebralspin fluidinthebrainat a therapeutically
effective concentration [74,75]. Further in vivo studies should clarify
whether inhibition of NF-kB signaling or TNF-a production results
in protective effects, and if the NF-kB pathway results a convenient
new target for the development of therapeutic strategies for the
treatment of CNS commitment in HUS patients.
Given the narrow interaction between ASTs and brain ECs,
local concentration of secreted astrocytic factors in response to Stx
is extremely relevant to understand the role of cerebral
inflammation and its relation with the microvascular injury and
BBB alterations in HUS. Primary alteration of the BBB after
STEC infection as a consequence of the systemic inflammation
and/or bacterial-derived factors may leave the brain unprotected
to the entry of Stx and LPS. Thereafter, ASTs inflammatory
response creates an amplification loop that potentiates the initial
endothelial damage affecting even more the integrity of the BBB.
Results from this work and the bibliographical precedents,
stimulate the accomplishment of a more detailed in vivo study to
determine the contribution of brain inflammatory response, and
particularly of perivascular ASTs to understand the neuropathol-
ogy of HUS.
Materials and Methods
Ethics statement
Human normal samples were obtained from voluntary donors.
This study was performed according to institutional guidelines
(National Academy of Medicine, Buenos Aires, Argentina) and
received the approval of the institutional ethics committee and
written informed consent was provided by all the subjects.
Human donors
Human normal blood samples were obtained from voluntary
donors by venipuncture and drawn directly into plastic tubes
containing 3.8% sodium citrate. Human umbilical cords were
obtained from normal placentas, and placed in a sterile container
filled with a transfer buffer.
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Stx1 was kindly provided Dr Sugiyama Junichi (Denka Seiken
CO Ltd, Nigata, Japan). Purity was analyzed by the supplier by
high performance liquid chromatography (HPLC). Stx1 prepara-
tion was checked for endotoxin contamination by the Limulus
amoebocyte lysate assay and contained ,40pg lipopolysaccharide
(LPS)/mg of pure protein.
PMN purification and platelets preparation
Human PMN were isolated by Ficoll-Hypaque gradient
centrifugation (Ficoll Pharmacia, Uppsala; Hypaque, Wintthrop
Products, Buenos Aires, Argentina) and dextran sedimentation, as
previously described [76]. Viability was assessed by trypan blue
exclusion and purity was determined by Turk’s solution staining.
Only fractions containing at least 80% of PMN were used.
Platelet rich plasma (PRP) was obtained by centrifugation of the
blood samples (1806g for 10 min). For washed platelet suspen-
sions, PRP was centrifuged in the presence of prostacyclin (PGI2,
75 nM), and the platelets were then washed in washing buffer
(140 mM NaCl, 10 mM NaHCO3, 2.5 mM KCl, 0.5 mM
Na2HPO4, 1 mM MgCl2, 22 mM sodium citrate, 0.55 mM
glucose, 0.35% BSA, pH 6.5) washed platelets were resuspended
in Tyrode’s buffer and the platelet number was adjusted.
ASTs isolation
ASTs were prepared from rat cerebral tissue cortex as
previously described [77]. Briefly, cerebral hemispheres were
dissected out from newborn rats, free of meninges, and dissociated
by gentle pipetting on DMEM/Ham’s F12 media (GIBCO,
Invitrogen) (1:1 v/v) containing 5 mg/ml streptomycin and 5 U/
ml penicillin, supplemented with 10% fetal calf serum (FCS)
(GIBCO). The cell suspensions were seeded into poly-L-lysine-
coated 75 cm
2 tissue culture flasks (Corning). After 14 days in
culture, ASTs were separated from microglia and oligodendro-
cytes by shaking twice, for 24 h each, in an orbital shaker. The
purity of ASTs cultures was 90–95%, as assessed by GFAP
immunostaining by flow cytometry.
ASTs culture and treatments
ASTs (7610
4) were seeded into 24 well-plates and cultured in
DMEM media containing 10% FCS and supplemented with
5 mg/ml streptomycin and 5 U/ml penicillin (complete DMEM).
Cultures were maintained at 37uC in a humidified 5% CO2
atmosphere. After 24 h, ASTs were mock-treated (control) or
treated with LPS (0.5 mg/ml); Stx1 (10 ng/ml) or LPS+Stx1 (Stx1
added 18 h after LPS). Purified LPS derived from E. coli O111:B4
(Sigma) was used.
The inhibitor (E)-3-[4-methylphenylsulfonyl]-2-propenenitril
(BAY 11-7082; Biomol) was used for suppressing NF-kB
activation. BAY 11-7082 (40 mM) was added to ASTs cultures
30 min before treatment. A soluble tumor necrosis factor receptor
(Etanercept; Enbrel, Wyeth Inc.) was used to block ASTs secreted
TNF-a action. Etanercept (5 ng/ml) was added to ASTs cultures
10 min before treatment.
ASTs conditioned media
Conditioned medium from confluent cultures of ASTs (CM-
ASTs) grown in complete DMEM was collected every 24 h. CM-
ASTs from untreated ASTs (CM-Control) or CM-ASTs treated
with LPS and/or Stx1 (CM2LPS, CM2Stx1 and
CM2LPS+Stx1) were collected 18 h after Stx1 treatment. The
CM-ASTs were centrifuged to eliminate cells and debris and
sterilized by filtration. The CM-ASTs were aliquoted and stored at
280uC until used. Before CM-ASTs were employed in experi-
mental cultures, 7 mg/ml of Polymyxin B (Px, Sigma) and an
antibody (Ab) against Stx (anti-Stx; final dilution 1:100 Toxin
Technology, Catalog Number STX1-9C9; anti-STX1 alpha
subunit, mouse monoclonal antibody IgG) were added to the
CM-ASTs. Proper doses of the Px and anti-Stx to block the effects
of remnant traces of LPS and/or Stx1 have been previously tested
and validation tests are summarized in Figure S1 [13].
Endothelial cell culture
Human umbilical vascular endothelial cells (HUVECs) were
obtained by collagenase digestion according to the method of Jaffe
et al [78]. Cells were seeded until confluence on 1% gelatin-coated
25-cm
2 tissue culture flasks and identified by their cobblestone
morphology and von Willebrand factor (VWF) antibody (Im-
munotech) binding. Cells were grown in RPMI 1640 medium
(HyClone) supplemented with 10% fetal bovine serum (FBS,
Gibco), heparin (100 mg/ml), endothelial cell growth factor
supplement (50 mg/ml), sodium pyruvate (2 mM), L-glutamine
(2 mM), penicillin (100 U/ml) and streptomycin (100 mg/ml)
(Sigma Chemical) at 37uC in a humidified 5% CO2 incubator.
HUVECs used for experiments were between first and third
passages. Cultured cells were identified as endothelial by their
morphology and VWF antibody binding.
Induction of the cerebral phenotype in HUVEC
CM-ASTs was used to induce a cerebral endothelium
phenotype in HUVEC (HUVECd). HUVEC (1610
5 cells) were
seeded into 24 well-plates and maintained in complete DMEM
during 24 h. Then, HUVEC were differentiated into HUVECd
by incubating them with CM-ASTs. After 24 h, HUVECd already
exhibited properties of cerebral endothelium and these features
lasted for up to 72 h even after removal of CM-ASTs.
Alkaline phosphatase activity determination for
endothelial cell differentiation and PMN adhesion
Endothelial Alkaline phosphatase (AlkP) was determined as
previously described with some modifications [79]. Briefly,
HUVEC and HUVECd were washed twice with PBS and
100 ml of 1% p-nitrophenyl phosphate disodium (p-NPP) in buffer
containing 1 mM MgCl2 and 100 mM 2-amino-2-methyl-1-
propanol (Sigma) was added to each well, and incubated at
37uC for 1 h. Then, 50 ml of stop solution (2 N NaOH) was added
and optical density was measured at 405 nm in Asys UVM340
Microplate Reader (Biochrom Ltd.). Enzymatic activity, defined as
dephosphorylated substrate produced in a given well during one
hour at 37uC was expressed in arbitrary enzymatic units (EU) and
calculated with the following equation:
EU DmM|h
{1
well

~ Abs-Absblanck ðÞ |1000= 18:6|0:47|1 ðÞ :
Similar procedure was applied for PMN adhesion with some
modifications [80]. Briefly, purified PMN were seeded onto CM-
ASTs treated HUVECd in a PMN/HUVECd ratio of 20:1 and
cultured for 3 h. Then, non-adherent PMN were removed by
vigorous washing with PBS and AlkP assay was performed by
incubating adherent cells for 1 h with 100 ml of 1% p-NPP in
diethanolamine buffer (1 M, pH 9-8). PMN-specific AlkP activity
was calculated subtracting basal AlkP activity from HUVECd
alone treated with the respective CM-ASTs. Data expressed as
percentages of AlkP enzymatic activity (%EA) was calculated as
follow:
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where AlkPtreatment was calculated as:
AlkPtreatment~ AbsPMNzHUVECd{AbsHUVECd ðÞ
|1000= 18:6|047|1 ðÞ
and AlkPtotal PMN is the total AlkP from unwashed control PMN.
ZO-1 and occludin expression
The cellular distribution of ZO-1 was evaluated microscopically
on the HUVECd grown in glass coverslips. After 24 h treatment
with DMEM or the different CM-ASTs, cells were pre-extracted
with 0.2% Triton X-100 in buffer containing 100 mM KCI,
3 mM MgCl2, 1 mM CaCl2, 200 mM sucrose, and 10 mM Hepes
(pH 7.1) for 2 min on ice and were immediately fixed with 2%
paraformaldehyde in PBS (30 min on ice). The fixed cells were
blocked for 30 min in 3% BSA, 0.25% Trito ´n X100 in PBS for
1 h. Primary antibodies (rabbit IgG anti-ZO-1, Invitrogen) were
diluted in the same solution and incubated with the cells for 1 h at
room temperature. Then cells were washed with PBS and
secondary antibody (FITC-labeled mouse anti-rabbit (1:200 final
dilution, Vector) was incubated during 1 h and finally washed.
Images were acquired using a FluoView FV1000 confocal
microscope (Olympus) equipped with a Plapon 606/1.42
objective lens and processed using FV10-ASW software (Olympus)
and Adobe Photoshop CS3 using only linear adjustments.
The expression levels of ZO-1 and occludin was determined by
intracellular flow cytometry (FACS) using a FACScan cytometer
(Becton Dickinson) following the labeling procedure described
above. For ZO-1 expression, the same antibodies were used. For
occludin, mouse IgM anti-Occludin (1:200 final dilution, Invitro-
gen) with PE-labeled rabbit anti-mouse IgG (1:200 final dilution,
DAKO) secondary antibody was used. Isotype matched control
immunostaining was performed in parallel. FCS Express program
(De Novo Sofware) for data analysis was employed. The analysis
was made on at least 30,000 events per sample.
F-actin disposition
HUVEC grown in glass coverslips were treated with DMEM or
the different CM-ASTs and 24 h later cells were fixed with 1%
paraformaldehyde in PBS during 20 min then washed and
permeabilized with 0.25% Triton X-100. F-actin was stained
using 10 mM TRITC-labeled phalloidin (Sigma) for 1 h at room
temperature. F-actin distribution was evaluated by confocal
microscopy using the above equipment by considering maximum
fluorescence intensity projections along the whole Z-stack.
Transendothelial Permeability Assays
HUVEC (2610
4 cells) were seeded onto the upper chamber of a
transwell system (0.3 mm pore size, Corning) and treated with
DMEMor CM-ASTs for 24 h to differentiate them into HUVECd.
In some experiments, HUVECd were additionally stimulated with
the different types of CM-ASTs (CM2Stx1, CM2LPS or CM2
Stx1+LPS) for another 24 h. The transendothelial passage of the
44 kD glycoprotein horse radish peroxidase (HRP) (Figure 1B) and
the bioactive ,75 kD multimeric protein Stx1 (Figure 4D) were
evaluated respectively as follow:
HRP translocation assay. The medium in the upper
chamber was removed and replaced by serum-free DMEM
containing 0.5 mmol/L (,2.2 U/ml) HRP (Sigma) and in the
lower chamber fresh DMEM was added. After 20 min. at 37uC
the activity of HRP was evaluated in the lower chamber using
commercial TMB substrate (Sigma). Briefly, 50 ml of TMB was
added to 50 ml of the recovered medium in the lower chamber.
After 10 min reaction was stopped using 100 mlo f1MH 2SO4
and optical density was determined at 450 nm. Relative
permeability to HUVEC was calculated as follows:
% Relative permeability~
AbsHUVECd{Absmedium ½  = AbsHUVEC{Absmedium ½  |100
Stx1 translocation assay. The medium in the upper
chamber was removed and replaced by serum-free DMEM
containing 30 ng/ml of Stx1 while in the lower chamber fresh
DMEM wasadded. After 30 min. at 37uC, the presenceof Stx1 was
determined in the lower chamber by evaluating Vero cytotoxicity
[81]. Briefly, 2610
4 Vero cells were seeded into a 96-well plate and
cultured in complete DMEM. After 24 h the medium was replaced
with0.1 ml of the supernatants collected from the lower chamber of
the transwell and incubated for 24 h. Then, cells were washed with
PBS and viable cells were fixed and stained with 0.2% crystal violet
in 20% methanol for 20 min at 37uC. Samples were washed and
lysed with 30% acetic acid solution. The resultant absorbance (Abs)
was measured at 550 nm. The percentage of Vero cytotoxicity was
calculated by the following formula:
% Vero cytotoxicity~100|
Abs of Vero cell cultured in DMEM   Abs of Vero cell ð
cultured in lower chamber supernatantsÞ=
Abs of Vero cell cultured in DMEM ðÞ :
Toxicity of CM-ASTs over HUVECd
HUVECd (1610
5 cells) grown in 24 well-plates were stimulated
with the different CM-ASTs during 24, 48, and 72 h. After
incubation, dead cells were washed away with PBS and remnant
cells were fixed and stained with crystal violet. Cytotoxicity on
treated HUVECd was determined microscopically using the
following equation:
% HUVECd cytotoxicity~100|
N0 HUVECd cultured in DMEM{N0 HUVECd cultured ð
with CM   ASTsÞ= N0 HUVECd cultured in DMEM ðÞ :
Stx1 receptor expression
Globoside Gb3 (CD77) expression was evaluated on HUVECd
stimulated by 24 h with the different CM-ASTs. As a positive control,
cells were stimulated with 0.5 mg/ml LPS. After incubation,
HUVECd were harvested, blocked with 3% BSA for 20 min and
exposed to rat anti-CD77 monoclonal antibody (clone 38-13; final
dilution 1:100; Immunothech) for 45 min at 4uC. Then, cells were
washed and incubated with FITC-conjugated secondary goat
antibody F(ab)92 anti-rat m chain (final dilution 1:200, Jackson
ImmunoResearchLab)in thedarkfor30 minat 4uC.Immunostained
cells were then washed and immediately analyzed by FACS as
indicated above. Isotype matched control immunostaining was
performed in parallel.
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The celldeath analysis of HUVECd treated 24 h with the different
CM-ASTs was performed 24 h after stimulation with a sub-toxic
dose of Stx1 (2 ng/ml). Detached dead cells were carefully collected
along with undetached cells. The Annexin V-FITC Apoptosis
Detection Kit (Calbiochem) was used according to manufacturer’s
instructions. Briefly, ASTs were incubated for 30 min with media
binding reagent and fluorescein isothiocyanate (FITC)-labeled
annexin V (AV, 1 mg/ml) in the dark at room temperature. Cells
were washed, resuspended in media binding buffer, and incubated for
10 min with propidium iodide (PI, 15 mg/ml). The percentage of
total death PI
+ AV
+/2 (PI
+/AV
2 plus PI
+/AV
+)a n dP I
2 AV
+ cells
was determined by FACS as indicated above.
Evaluation of cell activation
To evaluate HUVECd, PMN and platelet activation, ICAM-1, E-
selectin and CD11b, CD66b and P-selectin expression were
determined respectively by direct immunofluorescence using conju-
gated anti-human monoclonal antibodies and the surface expression
of these activation markers was evaluated by FACS. HUVECd were
stimulated with the CM-ASTs during 12 h or 6 h at 37uCf o rI C A M -
1 and E-selectin, respectively. Cells were washed and resuspended in
PBS 3% BSA and stained with a mouse monoclonal antibody
phycoerythrin (PE)-labeled anti-human CD54 (final dilution 1:50, BD
Pharmingen) for ICAM-1 determination or with a mouse monoclonal
antibody fluorescein isothiocyanate (FITC)-labeled anti-human
CD62E (final dilution 1:150, Immunotech) for E-selectin determina-
tion. PMN were stimulated with the different CM-ASTs for 90 min or
40 min for CD11b or CD66b determination, respectively. Then
PMN were collected in PBS 3% BSA and stained with PE-CD11b
(final dilution 1:250, Immunotech) and FITC-CD66b (final dilution
1/150, Immunotech). Platelets were stimulated with the different CM-
ASTs for 1.5 h at 37uC, washed and resuspended in PBS 3% BSA
and stained with a FITC-anti CD62P (anti-P-selectin antibody, final
dilution 1:50 BD Biosciences). Samples were incubated with the
specific antibody for 30 min at room temperature. Then, cells were
washed and suspended in 0.2 ml of ISOFLOW. In all cases, controls
of isotype-matched antibody were assayed in parallel. Data were
acquired and processed according the above indications. Cells were
identified and gated according to their respective forward and light
scattering (FSC/SSC) dot-plot profiles.
PMN adhesion (alkaline phosphatase)
Purified PMN were seeded onto CM-ASTs treated HUVECd in
a PMN/HUVECd ratio of 20:1 and cultured for 3 h. Then, non-
adherent PMN were removed by vigorous washing with PBS.
Alkaline phosphatase (AlkP) assay was performed in order to
measure PMN adhesion [80]. Briefly, adhered cells were incubated
for 1 h with 100 ml of 1% p-NPP in diethanolamine buffer (1 M,
pH 9-8) and PMN AlkP activity was determined as indicated above
subtracting basal AlkP activity from HUVECd alone treated with
the respective CM-ASTs. Data expressed as percentages of AlkP
enzymatic activity (% EA) was calculated as follow:
%E A ~ AlkPtreatment=AlkPtotal PMN ðÞ |100%
where AlkPtreatment was calculated as:
AlkPtreatment~ AbsPMNzHUVECd{AbsHUVECd ðÞ
|1000= 18:6|0:47|1 ðÞ
and AlkPtotal PMN is the total AlkP from unwashed control PMN.
PMN mediated cytotoxicity
PMN were seeded onto CM-ASTs treated HUVECd or onto
a transwell coculture system to avoid contact (20:1 PMN/
HUVECd ratio). After 8 h, non-adherent PMN and detached
dead HUVECd were removed by vigorous washing. Remnant
cells were stained with violet crystal. To assess PMN-mediated
HUVECd cytotoxicity, 3 random fields per treatment, were
photographed under 6006magnifications (Nikon, Coolpix
4500 digital camera; Nikon, Eclipse TE2000-S, inverted
microscope). Cell counts were performed as previously
described [13] using ImageJ software (U. S. National Institutes
of Health, Bethesda, Maryland). Percentage of cytotoxicity was
calculated as:
% Cytotoxicity~100{ N0 of treated HUVECd with ð ½
PMN=N0 of HUVECd w=oP M N Þ|100% 
Platelet adhesion (acid phosphatase)
Washed platelet (Pt) were seeded over treated HUVECd in a
Pt/HUVECd ratio of 40:1 and cultured for 3 h. Then, non-
adherent Pts were removed by vigorous washing with warm PBS.
Acid phosphatase (AcP) assay was performed in order to measure
Pt adhesion [82] Briefly, adherent Pts were incubated for 1 h with
150 ml of 5 mM p-NPP in citrate buffer (0.1 M, pH 5,4)
containing 0.1% Triton X-100 and enzymatic activity was
determined as indicated above. Arbitrary AcP units (EU) were
normalized to total EU present in unwashed control wells seeded
with equal number of Pts (EUtotal Pt) according to the following
equation: % EA=(EU/EUtotal Pt)6100%
Measurement of von Willebrand factor
von Willebrand factor (vWF) release was determined by ELISA
on supernatants from HUVECd after 24 h stimulation with the
different CM-ASTs following the manufacturer instructions
(Dako, Glostrup, Denmark). Results are expressed in ng/ml using
normal pooled plasma as standard (National Institute for
Biological Standars and Control, UK).
PMN transendothelial migration
HUVECd grown in the upper chamber of transwell were
treated 24 h with the different CM-ASTs and then PMN were
added (20:1 PMN/HUVECd ratio). After 1.5 h the number of
PMN that migrated across the HUVECd monolayer were
collected in the lower chamber of the transwell and counted
microscopically using a Neubauer chamber.
Statistical analysis
Statistical differences among treatments were determined using
paired t-test for two groups comparison and paired one-way
analysis of variance (ANOVA) followed by Bonferroni post test for
multiple comparison. A p value,0.05 was considered significant.
All tests were carried out using Prism 5.0 (Graph Pad Software, La
Jolla, CA).
Accession numbers
TNF-a P16599 (TNFA_RAT) Reviewed, UniProtKB/Swiss-Prot
NF-kB Q63369 (NFKB1_RAT) Reviewed, UniProtKB/
Swiss-Prot
Actin P68133 (ACTS_HUMAN) Reviewed, UniProtKB/
Swiss-Prot
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ProtKB/Swiss-Prot
ZO-1 Q07157 (ZO1_HUMAN) Reviewed, UniProtKB/
Swiss-Prot
Stx1 A subunit A8B1H9 (A8B1H9_ECO57) Unreviewed,
UniProtKB/TrEMBL
Stx1 B subunit C8UEK0 (C8UEK0_ECO1A) Unreviewed,
UniProtKB/TrEMBL
von Willebrand factor 04275 (VWF_HUMAN) Reviewed,
UniProtKB/Swiss-Prot
ICAM-1 P05362 (ICAM1_HUMAN) Reviewed, Uni-
ProtKB/Swiss-Prot
E-selectin P16581 (LYAM2_HUMAN) Reviewed, Uni-
ProtKB/Swiss-Prot
CD11b P11215 (ITAM_HUMAN) Reviewed, UniProtKB/
Swiss-Prot
CD66b P31997 (CEAM8_HUMAN) Reviewed, UniProtKB/
Swiss-Prot
P-selectin P16109 (LYAM3_HUMAN) Reviewed, Uni-
ProtKB/Swiss-Prot
Alkaline phosphatase P09923 (PPBI_HUMAN) Reviewed,
UniProtKB/Swiss-Prot
Etanercept P20333 (TNR1B_HUMAN) Reviewed, Uni-
ProtKB/Swiss-Prot
Supporting Information
Figure S1 Polymyxin B and anti-Stx1 antibody effec-
tively block the activating and cytotoxic effects of LPS
and Shiga toxin 1 on cell cultures. In order to rule out that
contaminating traces of LPS and/or Stx1 present in Astrocyte
conditioned media (CM-ASTs) may account for the observed
functional effects over HUVECd, PMN and platelets, we systemat-
ically pre-treated CM with Polymyxin B (Px) and antibodies against
Shiga toxin variant 1 and 2 (anti-Stx) before conducting the cultures
(M&M). A. Differentiated HUVEC were cultivated in complete
DMEMmediumalone (HUVECd) or stimulated with 0.5 mg/ml LPS
i nt h ep r e s e n c e( H U V E C d +LPS+Px) or absence of Px (HU-
VECd+LPS) during 24 h. The evaluation of the levels of Gb3 was
determined by FACS. Mean fluorescent intensity (MFI) of Gb3 in
HUVECd (Mean6 SE). *p,0.01 HUVECd+LPS vs. HUVECd,
##p,0.01 HUVECd+LPS vs HUVECd+LPS+Px (n=3, One way
ANOVA). (Right panel) Histograms of a representative experiment.
The augment of Gb3 (CD77) elicited in HUVECd after the
incubation with LPS (0.5 mg/ml, Sigma), is completely abrogated by
t h ep r e s e n c eo fP x( 7mg/ml, Sigma). B. Freshly isolated human
neutrophils were cultivated in complete RPMI medium alone (PMN)
or stimulated with 0.5 mg/ml LPS in the presence (PMN+LPS+Px) or
absence of Px (PMN +LPS) during 40 min. The evaluation of the
surface levels of CD11b was determined by FACS. Mean fluorescence
intensity relative to isotype control (RF) of CD11b (Mean6 SE).
*p,0.02 PMN+LPS vs. PMN; ##p,0.01 PMN+LPS vs
PMN+LPS+Px (n=3, One way ANOVA). The strong augment of
integrin CD11b expression in the cell surface of PMN treated with
above mentioned dose of LPS were completely blocked we addition of
Pxinculture media.C.Verocellswere cultivated incomplete DMEM
medium alone (Vero) or treated with 10 ng/ml of Stx1 in the absence
(Vero+Stx1), in the presence of anti-Stx antibody (Vero+ Stx1+anti-
Stx1) or with CM-ASTs treated with LPS+Stx1 with anti-Stx and
Polymyxin B addition (Vero+(CM2LPS+Stx1)+Px+anti-Stx). Viabil-
ity of crystal violet stained Vero cell monolayers was estimated by
measuring optical density at 550 nm (DO550). *p,0.05 (Vero+Stx1
vs. Vero; #p,0.05 Vero+Stx1 vs. Vero+Stx1+anti-Stx or Ver-
o+CM+LPS+Stx1+anti-Stx). (n=5, One way ANOVA). The toxicity
of Shiga toxin variant 1 (Stx1) over Vero cells cultures was inhibited by
adding neutralizing anti-Stx antibodies (final dilution 1/100, Toxin
Technology). Same results were verified in Vero cells cultures
conducted in the presence of CM2LPS+Stx1 pre-treated with a
combination of Px and anti-Stx. Note that LPS and Stx1
concentration employed in this control experiments are far above of
the contaminating traces that may be present in the CM-ASTs.
(TIF)
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